Clascoterone for Hair Loss: The Complete Guide

Why androgen-driven hair loss happens

Androgenetic alopecia is not a disease of insufficient blood flow or poor nutrition in most people. It is a receptor-level sensitivity problem. In genetically predisposed follicles, dihydrotestosterone (DHT) binds the androgen receptor in the dermal papilla and changes the transcriptional program of the follicle.

The consequence is miniaturisation: each successive hair cycle produces a shorter anagen (growth) phase, a thinner shaft and a smaller follicle, until the terminal hair is replaced by a barely visible vellus hair. The follicle is not dead — which is precisely why receptor-level intervention matters.

• DHT is produced locally in the scalp by 5-alpha reductase types 1 and 2.
• The androgen receptor is the final common pathway for that signal.
• Miniaturisation is progressive but, in early and mid-stage cases, partially reversible.
• Blocking the receptor locally addresses the signal without lowering systemic androgens.

How clascoterone works

Clascoterone is a cortexolone 17-alpha-propionate ester with a structure closely related to dihydrotestosterone itself. That structural similarity lets it occupy the androgen receptor competitively — it binds the receptor and prevents DHT from initiating the miniaturising cascade.

The decisive design feature is metabolic. Once clascoterone reaches the bloodstream it is rapidly hydrolysed to cortexolone, a metabolite with negligible androgen receptor activity. In practical terms the molecule is engineered to work in the skin and to stop working almost as soon as it leaves it.

Because it acts at the receptor rather than at the enzyme, clascoterone does not reduce circulating DHT the way 5-alpha reductase inhibitors do. It leaves systemic hormone levels broadly intact while competing for the receptor in the tissue where it is applied.

What the clinical evidence shows

Clascoterone's largest and most rigorous dataset comes from acne vulgaris: two identical Phase III randomised, vehicle-controlled trials of clascoterone 1% cream in more than 1,465 patients, which led to regulatory approval of the cream formulation in the United States in 2020. Those trials established the safety profile of topical clascoterone in a large population.

For androgenetic alopecia, the pivotal evidence is a Phase II dose-ranging study of clascoterone solution applied twice daily in men with androgenetic alopecia, which reported dose-dependent improvement in target-area hair count against vehicle, with the higher concentrations performing best. Phase III programmes in androgenetic alopecia have been pursued on the strength of that signal.

The honest summary: the mechanism is well characterised, the topical safety record in large trials is strong, and the hair-count signal is positive and dose-dependent — but the alopecia evidence base is younger and smaller than that of minoxidil or finasteride.

Realistic timeline and expectations

Hair biology sets the pace, not the molecule. A follicle that has been switched into a miniaturising program needs at least one full cycle turn before a thicker shaft becomes visible.

• Weeks 1–8: no visible change. Scalp tolerability and routine consistency are what matter.
• Months 3–4: reduced shedding is usually the first observable endpoint.
• Months 4–6: early density and calibre changes in the vertex and mid-scalp.
• Months 6–12: the realistic window for a meaningful, photograph-visible result.

How a topical solution is used

A calibrated dropper delivers 1.5 mL to a dry or towel-dry scalp, parted into sections so the solution reaches the skin rather than the hair. It is massaged in briefly and left to absorb; hands are washed afterwards.

Consistency outweighs quantity. Applying more solution does not accelerate the follicular cycle, and irregular application is the single most common reason people conclude a topical 'did not work'.

Who it suits — and who should seek advice first

Receptor-level intervention is most useful in early to mid-stage patterned thinning where follicles are miniaturised but still present. Areas of long-standing, fully smooth scalp have lost the follicular units entirely and will not respond to any topical.

Anyone who is pregnant or nursing, has an active scalp condition, is using prescription scalp medication, or has an endocrine diagnosis should speak with a qualified clinician before starting.